KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Other Working Capital Changes (2016 - 2025)

BeOne Medicines (ONC) has disclosed Other Working Capital Changes for 11 consecutive years, with $56.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes changed N/A to $56.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a N/A change, with the full-year FY2025 number at $1.3 million, changed N/A from a year prior.
  • Other Working Capital Changes was $56.5 million for Q4 2025 at BeOne Medicines, up from -$100.6 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $90.2 million in Q3 2023 to a low of -$100.6 million in Q3 2025.
  • A 5-year average of $741947.4 and a median of $1.4 million in 2022 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: tumbled 1449.54% in 2021, then soared 6331.88% in 2023.
  • BeOne Medicines' Other Working Capital Changes stood at -$72.4 million in 2021, then surged by 80.07% to -$14.4 million in 2022, then crashed by 105.9% to -$29.7 million in 2023, then surged by 30.29% to -$20.7 million in 2024, then skyrocketed by 372.92% to $56.5 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Other Working Capital Changes are $56.5 million (Q4 2025), -$100.6 million (Q3 2025), and $75.1 million (Q2 2025).